Product
UGN-103
1 clinical trial
2 indications
Indication
Bladder CancerIndication
Bladder Urothelial CarcinomaClinical trial
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low-grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate-risk (IR) of RecurrenceStatus: Not yet recruiting, Estimated PCD: 2025-03-01